Category Archives: Cancer Research

Distinguished professor Dr. Mikhail Blagosklonny dedicates his life to Oncology Research

Mikhail Blagosklonny works as the Professor of Oncology at the Roswell Park Institute of Cancer. Dr. Mikhail has centered his work on studying on anti-aging and the possibility of preventing healthy cells from being cancerous. He has carried out several research studies that focus on cancer therapies. Mikhail Blagosklonny is popular for his work in TOR signaling during aging. The research concentrates on the relationship that exists between Rapamycin and extending one’s lifespan. Apart from his research activities, Dr. Blagosklonny has become highly active in publishing several academic journals. One of the leading journals where he publishes his work is Oncotarget.

Blagosklonny earned his education from First State Pavlov Medical University situated at St. Peterburg in Russia. He received his M.D. in the field of internal medicine and a Ph.D. in the area of cardiology research and experimental medicine on LinkedIn. After his studies, he moved to the United States where he became a professor at the New York Medical School located in Valhalla in 2002. Mikhail Blagosklonny took a position as the senior scientist at the Ordway Research Institute. He held the position until the year 2009. He got appointed to become the Professor of Oncology.

Since moving to Rowell Park Cancer Institution, Blagosklonny research work on has focused on cancer and finding therapies that separate healthy cells from cancer infected cells. He wants to create a mechanism that should kill cancer cells and leave the healthy cells. He has developed several theories and treatment options for aging and anti-aging medications on Google. Mikhail Blagosklonny has since come up with several publications that relate to clinical trials, oncology, and hematology. One of his recent books was in the research of how Dual Inhibitors reduce cellular division.

Mikhail Blagosklonny has made several other publications that seek to find the relationship between longevity and calorie restriction. He created a purported immortal being known as Koschei who used anti-aging drugs on Nature. Koschei lived in Northern Europe, ate very little, and possessed a bony body. The publication discussed the use of other drugs to extending life through calorie restriction. His research saw him use Rapamycin to investigation fat gain prevention. He carried out the study of weight gain in rats.

How Clay Siegall Has Improved Seattle Genetics And Healthcare In General

Dr. Clay Siegall has made notable strides in the healthcare sector by working with leading companies to avail solutions to problems ailing the industry. One of the companies he works with is the Mirna Therapeutics, a company focused on commercializing and developing microRNA therapeutics. He received the appointment to work as an outside director in 30th January, 2013.

One of the qualities that inspired the company to hire him is his expansive experience and knowledge in the field of clinical medicine, and they expressed confidence in the appointment citing that he would be a vital addition to their team.

More about Mirna Therapeutics
Mirna Therapeutics deals with the manufacture and commercialization of microRNA Therapeutics. The company applies its own unique strategies developed by their scientists and professionals in-licensed and the portfolio of the company contains more than 300 miRNAs that can be applied in oncology and several other diseases.

Mirna Therapeutics, located in Texas, was founded in 2007 and has all through invested in research and development of treatment methods for cancer through the Cancer Prevention and Research Institute.

Seattle Genetics
Founded in 1998 by Clay Siegall, Seattle Genetics is a biotechnology company that has specialized in the development of cancer treatment methods through antibody-drug conjugates technology, which works by empowering monoclonal antibodies in the treatment of cancer.

Having been in the industry for more than one decade, Seattle Genetics has developed industry-leading and proprietary technology that works through monoclonal antibody specifics that help to deal with tumor-associated antigen and cell-killing agents. The company has also been having clinical trials and volunteers can get in to help in the process, which includes testing of various diseases to come up with ideas for the development of drugs.

About Dr. Clay Siegall
Clay B. Siegall is a co-founding member of Seattle Genetics and is the current CEO and President of the company. Siegall is trained as a scientist and his area of specialization is cancer therapeutics, which explains the reason he built Seattle Genetics on a foundation that respects scientific innovation, research and drug development.

Clay Siegall’s leadership has been vital in enhancing the development of antibody-drug conjugates and helped to secure the FDA approval in 2011. Through his support, Seattle Genetics has entered into several licenses for the ADC technology, which include major players in the industry like GlaxoSmithKline, Pfizer, AbbVie and Gentech.